Abstract:e13601 Background: The drug approval and clinical use of immune checkpoint inhibitors (ICIs) were different among de novo and previously treated cancer patients. The purpose of this study is to investigate progression-free survival (PFS) and objective response rate (ORR) as earlier primary endpoints in previously treated advanced or metastatic solid cancers in immunotherapy era. Methods: This systematic review included phase 2 and 3 clinical trials in previously treated advanced or metastatic solid cancers receiving ICIs, through literature search on databases up to 2022. Quality control was performed, where studies with high risk of bias were excluded. Prediction models were first established using randomized controlled trials (RCTs), and then externally validated in the phase 2 non-randomized trials. Trial-level surrogacy analysis was conducted by correlating PFS hazard ratio (HR) and overall survival (OS) HR. Correlation analysis within checkpoint inhibitor arms was performed between ORR, 3-, 6-, and 9-month PFS rates and 12-month OS rate. The correlation was evaluated using the Pearson correlation coefficient r in weighted linear regression, with weight equal to patient size. High, medium strength, and low correlation was defined as r ≥ 0.85, 0.7 < r < 0.85, and r ≤ 0.7, respectively. Sensitivity analyses were performed to assess the consistency of predictive model by leaving trials of one cancer type out at a time. Results: A total of 64 phase 2 or 3 RCTs with 22,011 patients and 96 phase 2 non-randomized trials with 10,288 patients were included in modeling and validation, respectively. The most common primary endpoint in RCTs and non-randomized trials was OS (38 [59%]) and ORR (72 [75%]). The mostly used endpoint assessment criteria were RECIST v1.1 in both RCTs (59 [92%]) and non-randomized trials (88 [92%]). In trial-level surrogacy, PFS HR showed a low correlation with OS HR ( r, 0.52; 95% confidence interval [CI], 0.23–0.78). Within the checkpoint inhibitor treatment arms in RCTs, there was a high correlation between 6-month PFS and 12-month OS ( r, 0.85; 95% CI, 0.76–0.90), and 9-month PFS and 12-month OS ( r, 0.85; 95% CI,0.80–0.90), with a medium strength correlation between 3-month PFS and 12-month OS ( r, 0.79; 95% CI, 0.65–0.89) and a low correlation between ORR and 12-month OS ( r, 0.13; 95% CI, 0.10–0.76). In external validation, when 6-month PFS was used to predict 12-month OS, there was a good calibration between actual and predicted 12-month OS. Sensitivity analysis demonstrated reasonable overall consistency. Conclusions: For phase 2 non-randomized, observational checkpoint inhibitor trials enrolling previously treated advanced or metastatic solid cancers, we recommended 6-month PFS rate as primary surrogate endpoint. For RCTs, gold standard endpoint OS should be persistently used and should not be replaced by earlier endpoints PFS or ORR.

Surrogate endpoints for overall survival in randomized clinical trials testing immune checkpoint inhibitors: a systematic review and meta-analysis

Immune Checkpoint Inhibitors and Survival Outcomes in Brain Metastasis: A Time Series-Based Meta-Analysis

Evaluation of MPR and pCR as surrogate endpoints for survival in randomized controlled trials of neoadjuvant immune checkpoint blockade in resectable in non-small cell lung cancer.

Surrogate Endpoints for Overall Survival in Anti-Programmed Death-1 and Anti-Programmed Death Ligand 1 Trials of Advanced Melanoma

Predictive Value of Radiological Response, Pathological Response and Relapse-Free Survival for Overall Survival in Neoadjuvant Immunotherapy Trials: Meta-Analyses of Individual Patient Data

Surrogate Endpoints for Overall Survival in Immune-Oncology Trials of Advanced Gastro-Esophageal Carcinoma

Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials

Consideration of Surrogate Endpoints for Overall Survival Associated With First-Line Immunotherapy in Extensive-Stage Small Cell Lung Cancer

Surrogate End Points for Overall Survival in Patients with Advanced Non-Small-cell Lung Cancer in Trials of Immunotherapy.

Surrogate endpoints for overall survival in advanced hepatocellular carcinoma: A meta-analysis.

Immune-related adverse events as potential surrogates of immune checkpoint inhibitors' efficacy: a systematic review and meta-analysis of randomized studies

Correlation between surrogate endpoints and overall survival in unresectable hepatocellular carcinoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis

Predictive value of radiological response, pathological response and relapse-free survival for overall survival in neoadjuvant immunotherapy trials: pooled analysis of 29 clinical trials

Immune-Related Adverse Events Can Predict Progression-Free and Overall Survival In Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors

Abstract 3638: Pathologic endpoints as surrogates for survival endpoints in neoadjuvant immunotherapy clinical trials for non-small cell lung cancer

Progression‐free survival assessed per immune‐related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune‐checkpoint inhibitors in lung cancer: A systematic review and meta‐analysis

Correlation of Milestone Restricted Mean Survival Time Ratio With Overall Survival Hazard Ratio in Randomized Clinical Trials of Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.

Exploring the most appropriate primary endpoint of immune checkpoint inhibitors for previously treated advanced solid cancers.

951P The relationship between overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) in immune checkpoint inhibitor clinical trials of head and neck squamous cell carcinoma (HNSCC): A systematic review and meta-analysis

Impact of Clinicopathological Characteristics on Survival in Patients Treated with Immune Checkpoint Inhibitors for Metastatic Melanoma.

36P Progression-free survival as a surrogate for overall survival in trials of immune checkpoint inhibitors in pan cancer evaluated by RECIST 1.1